PubRank

Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX)

Clinical Trial ID NCT03255252

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03255252

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014 40.30
2 Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta 1996 7.79
3 Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009 5.79
4 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
5 Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013 3.26
6 Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995 2.58
7 Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009 2.04
8 High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007 1.96
9 Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004 1.90
10 Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 2010 1.73
11 Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008 1.57
12 Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res 2008 1.54
13 Autophagy inhibition radiosensitizes in vitro, yet reduces radioresponses in vivo due to deficient immunogenic signalling. Cell Death Differ 2013 1.49
14 Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008 1.44
15 Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 2003 1.40
16 Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997 1.29
17 Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014 1.26
18 Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001 1.25
19 ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene 2012 1.19
20 Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996 1.18
21 HPV infection in Europe. Eur J Cancer 2009 1.10
22 Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. Int J Cancer 2006 1.05
23 Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma. Int J Cancer 2013 1.05
24 Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol 2012 1.04
25 Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015 1.03
26 Tim-3 expression defines regulatory T cells in human tumors. PLoS One 2013 1.02
27 Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000 1.02
28 The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer 2010 0.98
29 Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 1994 0.93
30 Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J Gen Virol 1996 0.90
31 Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res 2014 0.90
32 Radiotherapy and immunogenic cell death. Semin Radiat Oncol 2015 0.89
33 Post-transcriptional and epigenetic regulation of antigen processing machinery (APM) components and HLA-I in cervical cancers from Uighur women. PLoS One 2012 0.87
34 CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol 1999 0.84
35 Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Gynecol Oncol 2003 0.83
36 CD8+ T lymphocytes are recruited to neoplastic cervix. J Clin Immunol 1995 0.83
37 Increase of human papillomavirus-16 E7-specific T helper type 1 response in peripheral blood of cervical cancer patients after radiotherapy. Immunology 2008 0.82
38 Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. J Virol 2000 0.79
39 Significance of perivascular lymphocytic infiltrates on survival of patients with invasive cervical cancer. J Immunother 2003 0.76
40 CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression. Oncoimmunology 2015 0.76
Next 100